Two selective internal radiation therapies (SIRTs), from Sirtex Medical and Boston Scientific respectively, will be made available on England’s National Health Service for treating advanced liver cancer but a third one, from Quirem Medical/Terumo, will not.
The move follows a health technology assessment (HTA) by the National Institute for Health and Care Excellence (NICE), which examined the cost-effectiveness of the locally targeted, one-off, microsphere-based treatments in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?